LXII: The Chronicles of Professor Tsugua Senob and the Tumor the Immune System Saw but Ignored
The lecture began before Professor Tsugua arrived.
Musa was scrolling through his phone.
“How does someone become a professor of oncology and immunology and still not cure cancer?” he asked.
A few students laughed.
“Because cancer is complicated,” Aisha replied.
“Complicated how?” Musa pressed. “If the immune system can detect viruses, bacteria, parasites, and even transplanted organs, why can't it eliminate cancer?”
That was when Professor Tsugua entered.
He heard the question, walked to the board, and wrote:
If cancer is foreign, immunity should destroy it.
If cancer is self, immunity should tolerate it.
The room fell silent.
“The tragedy of cancer,” he said, turning to face them, “is that both statements are partly true.”
He paused.
“Cancer begins as self.”
“A normal epithelial cell. A normal lymphocyte. A normal melanocyte.”
“It carries your DNA and many of your proteins.”
Sadiq nodded.
“So tolerance becomes a problem.”
“Exactly.”
Tsugua wrote:
Immune Surveillance
“The immune system continuously detects and removes abnormal cells. We know this because immunodeficient individuals have a higher risk of certain cancers, particularly lymphomas and virus-associated malignancies.”
Musa frowned.
“If the immune system sees cancer, why doesn't it always win?”
Tsugua wrote three words beneath the first heading.
Elimination
Equilibrium
Escape
“The Three Es of Cancer Immunoediting.”
He pointed to the first.
“During elimination, cytotoxic T cells, NK cells, macrophages, and interferons destroy transformed cells before they become clinically apparent.”
Then the second.
“Equilibrium is a stalemate. The immune system contains the tumor, but does not eradicate it.”
Kunle looked up.
“So some cancers may be held in check for years?”
“Possibly.”
Tsugua tapped the final word.
“Escape.”
“The surviving tumor cells are often the ones least visible to the immune system. Over time, selection favors cells that evade detection or suppress immune responses.”
Aisha nodded.
“The immune system is selecting for better escape mechanisms.”
“Precisely.”
He wrote:
PD-L1
“Some tumors express inhibitory molecules such as PD-L1, which bind PD-1 on T cells and suppress their activity.”
Musa blinked.
“So the tumor tells the immune system to stand down.”
“In effect, yes.”
“Others reduce MHC expression, recruit regulatory T cells, or create immunosuppressive microenvironments.”
Fatima looked thoughtful.
“So the immune system isn't necessarily blind to cancer.”
“Often it is not.”
Chinedu raised a hand.
“Then why don't more cancers develop?”
Tsugua looked around the room.
“Because most are eliminated before we ever know they existed.”
The room became quiet.
He wrote one final phrase.
Checkpoint Inhibition
“One of the great breakthroughs in oncology came from realizing that, in many patients, the immune system was present but restrained.”
“Checkpoint inhibitors targeting PD-1 or CTLA-4 release those brakes and restore antitumor activity.”
Aisha smiled.
“So immunotherapy doesn't always teach the immune system what cancer is.”
“Correct.”
“It often reminds the immune system what it already recognized.”
Tsugua closed his folder.
“The greatest challenge in immunology is not recognizing what is foreign.”
He paused.
“It is deciding what to do when the threat looks almost exactly like self.”
The fire alarm sounded.
Sharp.
Brief.
The class looked up.
The alarm stopped.
Tsugua glanced toward the ceiling.
“The most dangerous enemies,” he said quietly, “are often the ones that learned how to look familiar.”
Class ended.
#TalesOfTsuguaSenob